Flurbiprofen axetil

Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway^{[1][2][3][4][5]}. In Vitro:Flurbiprofen axetil (0-160 nM, 1-6 days) does not affect the proliferation and activity, but inhibits migration and invasion in BT-549 and MDA-MB-231 cells^[2]. In Vivo:Flurbiprofen axetil (0.1 g/100 mL, drops into the eyes, 2 times/day, 24 h) has anti-inflammation effect in endotoxin-induced uveitis (EIU) rabbit model^[1].
Flurbiprofen axetil (10  mg/kg, i.p., once every two days, 28 days) inhibits breast cancer metastasis via inhibiting MEK/ERK signaling pathway in nude mice model^[2].
Flurbiprofen axetil (10 mg/kg, i.v., once) could promote a neuroprotective effect by, or in part, activation of PPAR-γ after focal cerebral ischemia in rat^[3].
Flurbiprofen axetil (5-10 mg/kg, i.v., once) protects the brain from cerebral I/R injury through reducing inflammation and brain edema in global cerebral ischemia male SD rat^[4].
Flurbiprofen axetil (10 mg/kg, i.v., once) can reduce the inflammatory response and cognitive function through the AMPKα/NF-κB signaling pathway.in formalin-induced MCI SD rat model^[5].